These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
270 related articles for article (PubMed ID: 30466992)
1. Natural products for the prevention and treatment of kidney disease. Chen DQ; Hu HH; Wang YN; Feng YL; Cao G; Zhao YY Phytomedicine; 2018 Nov; 50():50-60. PubMed ID: 30466992 [TBL] [Abstract][Full Text] [Related]
2. Tanshinone IIA attenuates renal fibrosis and inflammation via altering expression of TGF-β/Smad and NF-κB signaling pathway in 5/6 nephrectomized rats. Wang DT; Huang RH; Cheng X; Zhang ZH; Yang YJ; Lin X Int Immunopharmacol; 2015 May; 26(1):4-12. PubMed ID: 25744602 [TBL] [Abstract][Full Text] [Related]
3. Central role of dysregulation of TGF-β/Smad in CKD progression and potential targets of its treatment. Chen L; Yang T; Lu DW; Zhao H; Feng YL; Chen H; Chen DQ; Vaziri ND; Zhao YY Biomed Pharmacother; 2018 May; 101():670-681. PubMed ID: 29518614 [TBL] [Abstract][Full Text] [Related]
4. Ureic clearance granule, alleviates renal dysfunction and tubulointerstitial fibrosis by promoting extracellular matrix degradation in renal failure rats, compared with enalapril. Huang YR; Wei QX; Wan YG; Sun W; Mao ZM; Chen HL; Meng XJ; Shi XM; Tu Y; Zhu Q J Ethnopharmacol; 2014 Sep; 155(3):1541-52. PubMed ID: 25087615 [TBL] [Abstract][Full Text] [Related]
5. Prediction of the mechanisms of action of Shenkang in chronic kidney disease: A network pharmacology study and experimental validation. Qin T; Wu L; Hua Q; Song Z; Pan Y; Liu T J Ethnopharmacol; 2020 Jan; 246():112128. PubMed ID: 31386888 [TBL] [Abstract][Full Text] [Related]
6. A review on the efficacy and mechanism of action of Shenkang injection against chronic kidney disease. Zou JJ; Zhou XT; Chen YK; Liu JL; Wang C; Ma YR; Wang L Biomed Pharmacother; 2020 Dec; 132():110833. PubMed ID: 33035831 [TBL] [Abstract][Full Text] [Related]
7. Metabolomics insights into chronic kidney disease and modulatory effect of rhubarb against tubulointerstitial fibrosis. Zhang ZH; Wei F; Vaziri ND; Cheng XL; Bai X; Lin RC; Zhao YY Sci Rep; 2015 Sep; 5():14472. PubMed ID: 26412413 [TBL] [Abstract][Full Text] [Related]
8. Colon may provide new therapeutic targets for treatment of chronic kidney disease with Chinese medicine. Zou C; Lu ZY; Wu YC; Yang LH; Su GB; Jie XN; Liu XS Chin J Integr Med; 2013 Feb; 19(2):86-91. PubMed ID: 23371456 [TBL] [Abstract][Full Text] [Related]
9. Bisdemethoxycurcumin protects against renal fibrosis via activation of fibroblast apoptosis. Jin F; Jin Y; Du J; Jiang L; Zhang Y; Zhao Z; Yang B; Luo P; He Q Eur J Pharmacol; 2019 Mar; 847():26-31. PubMed ID: 30660576 [TBL] [Abstract][Full Text] [Related]
10. The smell of renal protection against chronic kidney disease: Hydrogen sulfide offers a potential stinky remedy. Dugbartey GJ Pharmacol Rep; 2018 Apr; 70(2):196-205. PubMed ID: 29471067 [TBL] [Abstract][Full Text] [Related]
11. Chinese Herbal Formulas and Renal Fibrosis: An Overview. Shen YL; Wang SJ; Rahman K; Zhang LJ; Zhang H Curr Pharm Des; 2018; 24(24):2774-2781. PubMed ID: 30156149 [TBL] [Abstract][Full Text] [Related]
12. Hirudin in the Treatment of Chronic Kidney Disease. Liu SJ; Cao YL; Zhang C Molecules; 2024 Feb; 29(5):. PubMed ID: 38474541 [TBL] [Abstract][Full Text] [Related]
13. ShenKang injection suppresses kidney fibrosis and oxidative stress via transforming growth factor-β/Smad3 signalling pathway in vivo and in vitro. Wu X; Guan Y; Yan J; Liu M; Yin Y; Duan J; Wei G; Hu T; Weng Y; Xi M; Wen A J Pharm Pharmacol; 2015 Aug; 67(8):1054-65. PubMed ID: 25864844 [TBL] [Abstract][Full Text] [Related]
14. Combined protective effects of oligo-fucoidan, fucoxanthin, and L-carnitine on the kidneys of chronic kidney disease mice. Chen YC; Cheng CY; Liu CT; Sue YM; Chen TH; Hsu YH; Huang NJ; Chen CH Eur J Pharmacol; 2021 Feb; 892():173708. PubMed ID: 33152336 [TBL] [Abstract][Full Text] [Related]
15. Natural products in traditional Chinese medicine: molecular mechanisms and therapeutic targets of renal fibrosis and state-of-the-art drug delivery systems. Song L; Zhang W; Tang SY; Luo SM; Xiong PY; Liu JY; Hu HC; Chen YQ; Jia B; Yan QH; Tang SQ; Huang W Biomed Pharmacother; 2024 Jan; 170():116039. PubMed ID: 38157643 [TBL] [Abstract][Full Text] [Related]
16. TGF-β/Smad Signaling Pathway in Tubulointerstitial Fibrosis. Yu XY; Sun Q; Zhang YM; Zou L; Zhao YY Front Pharmacol; 2022; 13():860588. PubMed ID: 35401211 [TBL] [Abstract][Full Text] [Related]